Journal: Current Cancer Drug Targets
Author(s): Senthamil R. Selvan, John P. Dowling, William K. Kelly and Jianqing Ling
Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
To access the article, please visit: http://benthamscience.com/journals/current-cancer-drug-targets/volume/16/issue/9/page/755/